Previous 10 | Next 10 |
Aurora Cannabis (NYSE: ACB ) initiated with Neutral rating and $7 (6% upside) price target at Piper Jaffray. More news on: Aurora Cannabis Inc., CV Sciences, Inc., Coherus BioSciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Thinly traded micro cap Mustang Bio (NASDAQ: MBIO ) announces that the California Institute for Regenerative Medicine has awarded a $9.28M grant to City of Hope to fund an ongoing Phase 1 study of HER2-specific CAR T candidate MB-103 in patients with HER2-positive breast cancer with brain ...
NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...
NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...
Mustang Bio (NASDAQ: MBIO ): Q2 GAAP EPS of -$0.29 misses by $0.04 . Cash equivalents, short-term investments and restricted cash of $83.1M Press Release More news on: Mustang Bio, Inc., Earnings news and commentary, Healthcare stocks news, ,
NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...
NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...
NEW YORK, July 24, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO ), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tum...
Mustang Bio (NASDAQ: MBIO ) is up 8.6% after hours following an initiation at Overweight by Cantor. More news on: Mustang Bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
NEW YORK, and MEMPHIS, Tenn., May 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic c...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s ma...
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficul...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...